Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.56 USD | -0.44% | -1.72% | -30.38% |
Financials (USD)
Sales 2024 * | 29.34M | Sales 2025 * | 90.7M | Capitalization | 191M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | -20M | EV / Sales 2024 * | 7.08 x |
Net Debt 2024 * | 16.8M | Net Debt 2025 * | 14.8M | EV / Sales 2025 * | 2.27 x |
P/E ratio 2024 * |
-2.87
x | P/E ratio 2025 * |
-8.83
x | Employees | 67 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.7% |
Latest transcript on Zevra Therapeutics, Inc.
1 day | -0.44% | ||
1 week | -1.72% | ||
Current month | -21.38% | ||
1 month | -20.83% | ||
3 months | -20.56% | ||
6 months | +4.35% | ||
Current year | -30.38% |
Managers | Title | Age | Since |
---|---|---|---|
Christal Mickle
FOU | Founder | 45 | 06-10-29 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 23-10-09 |
R. Clifton
DFI | Director of Finance/CFO | 51 | 15-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wendy Dixon
BRD | Director/Board Member | 68 | 23-04-24 |
Tamara Favorito
CHM | Chairman | 65 | 21-08-17 |
Director/Board Member | 56 | 23-04-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.44% | 4 M€ | -5.15% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 4.56 | -0.44% | 158,593 |
24-04-23 | 4.58 | +0.22% | 136,190 |
24-04-22 | 4.57 | +1.11% | 109,376 |
24-04-19 | 4.52 | +0.44% | 363,830 |
24-04-18 | 4.5 | -3.02% | 261,849 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.38% | 192M | |
+5.73% | 71.48B | |
+11.81% | 9.18B | |
-15.34% | 4.79B | |
+34.54% | 3.98B | |
+5.09% | 3.97B | |
+27.76% | 2.56B | |
-28.33% | 2.29B | |
-24.15% | 2.23B | |
+6.23% | 1.92B |
- Stock Market
- Equities
- ZVRA Stock